Sulopenem etzadroxil-probenecid
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Chemical and physical data | |
| Formula | C19H27NO7S3 |
| Molar mass | 477.61 g·mol−1 |
Sulopenem/sulopenem etzadroxil-probenecid is a new antibiotic currently being reviewed as an New Drug Application. Its parts: probenecid, a urocosuric (a drug which causes uric acid to be renally excreted) and an oral pro drug sulopenem (a carbapenem class antibiotic) under development for the treatment of drug resistant organisms including: ESBL, and N. gonorrhoeae.[1] in the setting of Uncomplicated Urinary Tract Infection. Sulopenem as a carbapenem is broad spectrum and possesses activity against anaerobes, gram positive and gram negative pathogens. It is marketed by Iterum Therapeutics [2] . The drug is being tested with the goal of being able to treat community acquired pneumonia, prostatitis, pelvic inflammatory disease, complicated intraabdominal infections with an easy transition from intravenous carbapenem antibiotics commonly used in the healthcare setting[3]. The monotherapy version (sulopenem) of the drug has been granted Qualified Infectious Disease Product status as of 2017 by the FDA giving it a fast track to approval.[4]
Microbiology[edit]
Broad spectrum similar to currently used carbapenems, but lacks coverage against Pseudomonas similar to ertapenem. [5]
Pharmacology[edit]
Sulopenem a beta-lactam carbapenem class antibiotic, and probenecid a urocosuric agent which reduces the excretion of sulopenem. Sulopenem is resistant to many beta-lactamases. [6] Probenecid has been used historically with antibiotics that are renally excreted as it causes competition in the kidneys and increases the life of renally excreted drugs.[7]
Regulatory approvals[edit]
Sulopenem/sulopenem etzadroxil-probenecid is currently undergoing phase 3 clinical trials for use in the United States[8]
Synonyms[edit]
References[edit]
- ↑ Dunne, M (Dec 31, 2020). "Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial". Open Forum Infectious Diseases. 7 (Suppl 1): S636. doi:10.1093/ofid/ofaa439.1417. PMC 7776693 Check
|pmc=value (help). - ↑ "Our promise responding to medical need". Iterum Therapeutics. Retrieved November 18, 2021.
- ↑ "Antibiotics Currently in Global Clinical Development". PEW Trusts. PEW Trusts. Retrieved November 18, 2021.
- ↑ "FDA Grants QIDP to Sulopenem for 4 New Indications". contagion live. Retrieved November 18, 2021.
- ↑ Nishino, K; Gotoh, N; Nishino, T (July 2001). "Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay". Antimicrob Agents Chemother. 45 (7): 1964–1971. doi:10.1128/AAC.45.7.1964-1971.2001. PMC 90586. PMID 11408209.
- ↑ "Sulopenem etzadroxil". Drug Information Portal. U.S. National Library of Medicine. Retrieved November 18, 2021.
- ↑ Butler D (2005). "Wartime tactic doubles power of scarce bird-flu drug". Nature. 438 (7064): 6. Bibcode:2005Natur.438....6B. doi:10.1038/438006a. PMID 16267514.
- ↑ "Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women". Clinical Trials. 17 December 2020. Retrieved 31 December 2021.
External links[edit]
This article "Sulopenem etzadroxil-probenecid" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sulopenem etzadroxil-probenecid. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
